{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"4"}],"units":"Participants"}],"description":"Determine safety of outcomes based on the number of safely treated participants by CTCAE version 5.0 tool","groups":[{"description":"ARM I: Patients receive 3 doses of tetanus before transplant and on days 15, and 60 post transplant.\n\nMelphalan: Given IV\n\nPeripheral Blood Stem Cell Transplantation--CD34 HSCT: Undergo autologous CD34 HSCT\n\nPeripheral Blood Stem Cell Transplantation--AHSCT: Undergo AHSCT\n\nT Cell-Depleted Hematopoietic Stem Cell Transplantation: Undergo autologous CD34 HSCT\n\nTetanus Toxoid Vaccine: Given IM","id":"OG000","title":"Arm I (Vaccine, CD34 Transplant, DLI)"},{"description":"Patients receive 3 doses of tetanus as in Arm I. Patients receive high-dose melphalan IV on day -2 and undergo AHSCT on day 0.\n\nMelphalan: Given IV\n\nPeripheral Blood Stem Cell Transplantation--AHSCT: Undergo AHSCT\n\nTetanus Toxoid Vaccine: Given IM","id":"OG001","title":"Arm II (Vaccine, Stem Cell Transplant)"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Through 180 days post-transplant","title":"Number of Safely Treated Participants (Feasibility and Safety)","type":"PRIMARY","unitOfMeasure":"Participants"}